Skip to main content
. Author manuscript; available in PMC: 2017 May 25.
Published in final edited form as: J Vitreoretin Dis. 2017 Jan 26;1(1):65–74. doi: 10.1177/2474126416683299

Figure 1.

Figure 1

Patient 1 is an 87 year old pseudophakic Caucasian woman with neovascular AMD and active choroidal neovascularization (A, B) who presented with intra- and sub-retinal fluid on OCT (C). She underwent multiple intravitreal ranibizumab and aflibercept injections (>20), but developed persistent fluid despite monthly injections of each and had a BCVA of 20/50 (C, D, E). She underwent dual therapy with intravitreal aflibercept and the dexamethasone intravitreal implant, which resulted in significant improvement of intra- and sub-retinal fluid and improved BCVA to 20/25 (F). She did not have any IOP elevation or injection- related complications.